<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910752</url>
  </required_header>
  <id_info>
    <org_study_id>Allo-HSCT-relapse-2015</org_study_id>
    <nct_id>NCT02910752</nct_id>
  </id_info>
  <brief_title>CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Salavge Chemotherapy With Cladribine, Cytarabine and Mitoxantrone Followed by Mobilized Peripheral Stem Cell Infusion From the Original Donor for Relapsed Patients After Allogeneic Stem Cell Transplantation: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For acute leukemia patients with early relapse after allogeneic stem cell transplantation,
      the overall outcome is poor. In this study, we evaluate the treatment outcome and safety of
      chemotherapy with Cladribine, cytarabine and mitoxantrone followed by peripheral stem cell
      support from the original donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For acute leukemia patients experienced relapse 6 months or less after allogeneic stem cell
      transplantation, the overall outcome is poor. In this study, we design a treatment protocol
      aiming to achieve complete remission for this high-risk group of patients with chemotherapy
      consisting of Cladribine (5mg/m2), cytarabine (1.5g/m2) and mitoxantrone （10mg/m2）for 5 days
      followed by infusion of mobilized peripheral stem cell from the original donor. For patients
      who failed to achieved remission,a second cycles will be given. For patients who achieved
      remission, the post-remission therapy is open depend on patient's intent: consolidation with
      one more cycle, second allo-HSCT with different donor or continuous DLI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission (Bone marrow)</measure>
    <time_frame>30 days after treatment</time_frame>
    <description>bone marrow aspiration performed on D30 after treatment. In case of less 5% blast with fully recovery of peripheral blood count is considered as CR. In case of less than 5% blast without fully recovered CBC is considered as CRi</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chimerism (bone marrow)</measure>
    <time_frame>30 days after treatment</time_frame>
    <description>chiremism analysis of patients bone marrow mononucleared cells at day 30 after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>6 months</time_frame>
    <description>patients remain alive 6 months after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse (bone marrow)</measure>
    <time_frame>6 months</time_frame>
    <description>bone marrow relapse within 6 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>6 months</time_frame>
    <description>patients died due to any treatment complication or other cause except for disease progression or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD (clinical evaluation and grading)</measure>
    <time_frame>6 months</time_frame>
    <description>grade II-IV acute GVHD and cGVHD if presented</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>CLAM|PBSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLAM+PBSC</intervention_name>
    <description>Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5</description>
    <arm_group_label>CLAM|PBSC</arm_group_label>
    <other_name>CLAMP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with acute leukemia relapsed within 6 months after previous allo-HSCT

          -  no active GVHD

          -  mobilized PBSC from the original donor available

        Exclusion Criteria:

          -  ECOG &gt;=3

          -  liver function/renal function damage (over 2 X upper normal range)

          -  active infection including CMV and EBV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU, M.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.</last_name>
    <phone>86-21-64370045</phone>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Wang, M.D.,</last_name>
    <phone>86-21-64370045</phone>
    <email>cclingjar@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rui Jin Hospital, Department of Hematology</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>hujiong@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ling Wang, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>cclingjar@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Program, Chief Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

